BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hassan S, Kahn MD, Saraiya N, Nori P. Treatment of a complex orthopaedic infection due to extensively drug-resistant Pseudomonas aeruginosa. BMJ Case Rep 2018;2018:bcr-2017-223202. [PMID: 29305368 DOI: 10.1136/bcr-2017-223202] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Tan X, Moenster RP. Ceftolozane-tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series. Ther Adv Drug Saf 2019;11:2042098619862083. [PMID: 31312424 DOI: 10.1177/2042098619862083] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
2 Cerioli M, Batailler C, Conrad A, Roux S, Perpoint T, Becker A, Triffault-Fillit C, Lustig S, Fessy MH, Laurent F, Valour F, Chidiac C, Ferry T. Pseudomonas aeruginosa Implant-Associated Bone and Joint Infections: Experience in a Regional Reference Center in France. Front Med (Lausanne) 2020;7:513242. [PMID: 33195289 DOI: 10.3389/fmed.2020.513242] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Gómez-Junyent J, Benavent E, Sierra Y, El Haj C, Soldevila L, Torrejón B, Rigo-Bonnin R, Tubau F, Ariza J, Murillo O. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model. Int J Antimicrob Agents 2019;53:612-9. [PMID: 30682497 DOI: 10.1016/j.ijantimicag.2019.01.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
4 Puzniak L, Dillon R, Palmer T, Collings H, Enstone A. Real-world use of ceftolozane/tazobactam: a systematic literature review. Antimicrob Resist Infect Control 2021;10:68. [PMID: 33832545 DOI: 10.1186/s13756-021-00933-8] [Reference Citation Analysis]